IBA renews interest in iSoft merger:
This article was originally published in Clinica
Executive Summary
Australian health information technology company IBA Health has submitted a revised cash offer of £166.3m ($330m), or 69p per share, for medical software supplier iSoft. IBA said it has agreed to buy around 56.6 million shares from iSoft shareholders, representing 24.3% of the company's issued capital. The revised offer trumps a 66p-per-share offer made on July 20 by fellow healthcare IT specialist CompuGROUP, based in Koblenz, German, which valued the deal at about £160m. IBA will receive a conditional investment of Aus$300m ($241m) from Allco Equity Partners on completion of the offer. Oxfordshire, UK-based iSoft claims to be one of the world's leading suppliers of advanced software applications for the healthcare sector, and was the main software supplier to the £12.4bn overhaul of the UK's National Health Service computer system.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.